Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David F McDermott

Showing results (121-130 of 227) with videos related to

Pageof 23
Sort By:
JNCI Cancer Spectrum|July 16, 2025
The Food and Drug Administration pooled analysis of overall survival according to depth of response in frontline advanced immune-oncology renal cell carcinoma trialsElaine Chang, Haley Gittleman, Chi Song, et al.
JAMA Oncology|May 30, 2020
Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell CarcinomaPraful Ravi, Charlene Mantia, Christopher Su, et al.
Cancer Immunology Research|May 28, 2015
Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell CarcinomaMarcella Callea, Laurence Albiges, Mamta Gupta, et al.
Oncotarget|December 22, 2017
Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expressionAly-Khan A Lalani, Kathryn P Gray, Laurence Albiges, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2019
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of AtezolizumabOmid Hamid, Luciana Molinero, Christopher R Bolen, et al.
Journal for Immunotherapy of Cancer|September 12, 2025
Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047Meredith M Regan, Paolo A Ascierto, Evan J Lipson, et al.
The Lancet. Oncology|December 11, 2012
Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort studyFabio A B Schutz, Mark M Pomerantz, Kathryn P Gray, et al.
Journal for Immunotherapy of Cancer|November 13, 2021
Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trialPatrick A Ott, Matthew Nazzaro, Kathleen L Pfaff, et al.
Clinical Genitourinary Cancer|July 16, 2023
Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808Bradley C Carthon, Se Eun Kim, David F McDermott, et al.
Cancer Medicine|July 19, 2017
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation statusBenjamin Izar, William Sharfman, F Stephen Hodi, et al.
Pageof 23

Showing results (121-130 of 227) with videos related to

Sort By:
Pageof 23
JNCI Cancer Spectrum|July 16, 2025
The Food and Drug Administration pooled analysis of overall survival according to depth of response in frontline advanced immune-oncology renal cell carcinoma trialsElaine Chang, Haley Gittleman, Chi Song, et al.
JAMA Oncology|May 30, 2020
Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell CarcinomaPraful Ravi, Charlene Mantia, Christopher Su, et al.
Cancer Immunology Research|May 28, 2015
Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell CarcinomaMarcella Callea, Laurence Albiges, Mamta Gupta, et al.
Oncotarget|December 22, 2017
Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expressionAly-Khan A Lalani, Kathryn P Gray, Laurence Albiges, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2019
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of AtezolizumabOmid Hamid, Luciana Molinero, Christopher R Bolen, et al.
Journal for Immunotherapy of Cancer|September 12, 2025
Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047Meredith M Regan, Paolo A Ascierto, Evan J Lipson, et al.
The Lancet. Oncology|December 11, 2012
Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort studyFabio A B Schutz, Mark M Pomerantz, Kathryn P Gray, et al.
Journal for Immunotherapy of Cancer|November 13, 2021
Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trialPatrick A Ott, Matthew Nazzaro, Kathleen L Pfaff, et al.
Clinical Genitourinary Cancer|July 16, 2023
Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808Bradley C Carthon, Se Eun Kim, David F McDermott, et al.
Cancer Medicine|July 19, 2017
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation statusBenjamin Izar, William Sharfman, F Stephen Hodi, et al.
Pageof 23